Pharmacotherapy of end-stage renal disease

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 4, 2010, Pages 597-613

  Schmid, Holger ^a   Schiffl, Helmut ^a   Lederer, Stephan R ^a  

^a KfH Nierenzentrum Muenchen Laim   (Germany)

Author keywords

Adherence; CKD MBD; Diabetes; Dyslipidemia; Erythropoietin; ESRD; Hemodialysis; Hypertension; Phosphate binder; Vitamin D

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE; DYNEP; EPOMAX; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERUMOXYTOL; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INSULIN; IRON; IRON CARBOXYMALTOSE; IRON DEXTRAN; METFORMIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHATE BINDING AGENT; RECOMBINANT ERYTHROPOIETIN; ROSUVASTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

ANAPHYLAXIS; ANEMIA; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE MONITORING; BONE METABOLISM; BRADYCARDIA; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTENSION; IRON DEFICIENCY ANEMIA; KIDNEY FAILURE; LOW DRUG DOSE; METABOLIC DISORDER; MINERAL METABOLISM; MORBIDITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; PURE RED CELL ANEMIA; RENAL REPLACEMENT THERAPY; REVIEW; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; THORAX PAIN; THROMBOSIS; VITAMIN D DEFICIENCY; VITAMIN DEFICIENCY;

ANEMIA; DATABASES, BIBLIOGRAPHIC; DYSLIPIDEMIAS; HUMANS; HYPERGLYCEMIA; HYPERPARATHYROIDISM, SECONDARY; HYPERPHOSPHATEMIA; HYPERTENSION; IRON COMPOUNDS; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PHARMACEUTICAL PREPARATIONS; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS;

EID: 77249176249     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903544494     Document Type: Review

References (109)

1. Levey AS, Coresh J, Balk E, et al.; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47
2. Obrador GT, Arora P, Kausz AT, et al. Level of renal function at the initiation of dialysis in the U.S. end-stage renal disease population. Kidney Int 1999;56:2227-35
3. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12
4. Grekas D, Bamichas G, Bacharaki D, et al. Hypertension in chronic hemodialysis patients: current view on pathophysiology and treatment. Clin Nephrol 2000;53:164-8
5. Agarwal R, Nissenson AR, Batlle D, et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003;115:291-7
6. Rocco MV, Yan G, Heyka RJ, et al.; HEMO Study Group. Risk factors for hypertension in chronic hemodialysis patients: baseline data from the HEMO study. Am J Nephrol 2001;21:280-8
7. Hörl MP, Hörl WH. Hemodialysis-associated hypertension: pathophysiology and therapy. Am J Kidney Dis 2002;39:227-44 • Scholarly review on the pathophysiology and pharmacotherapy of ESRD associated hypertension.
8. Ram CV, Fenves AZ. Management of hypertension in hemodialysis patients. Curr Hypertens Rep 2009;11:292-8
9. Lindley EJ. Reducing sodium intake in hemodialysis patients. Semin Dial 2009;22:260-3
10. Amar J, Vernier I, Rossignol E, et al. Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int 2000;57:2485-91
11. Mazzuchi N, Carbonell E, Fernández-Cean J. Importance of blood pressure control in hemodialysis patient survival. Kidney Int 2000;58:2147-54
12. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension 2005;45:811-7
13. Stidley CA, Hunt WC, Tentori F, et al. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol 2006;17:513-20
14. Ahmad S. Dietary sodium restriction for hypertension in dialysis patients. Semin Dial 2004;17:284-287
15. Thein H, Haloob I, Marshall MR. Associations of a facility level decrease in dialysate sodium concentration with blood pressure and interdialytic weight gain. Nephrol Dial Transplant 2007;22:2630-9
16. Chazot C. Managing dry weight and hypertension in dialysis patients: still a challenge for the nephrologist in 2009? J Nephrol 2009;22:587-97
17. Griffith TF, Chua BS, Allen AS, et al. Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 2003;42:1260-9
18. Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009;373(9668):1009-15 •• Systematic review and meta-analysis summarizing all trials with antihypertensive pharmacotherapy in dialysis patients.
19. K/DOQI Clinical Practice Guidelines. Am J Kidney Dis 2006;48 (Suppl 1):S1
20. Cannella G, Paoletti E, Delfino R, et al. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997;30:659-64
21. Tielemans C, Madhoun P, Lenaers M, et al. Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors. Kidney Int 1990;38:982-4
22. Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162:1401-8
23. Drüeke TB, Locatelli F, Clyne N, et al.; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84 •• Large prospective randomized trial evaluating the clinical effects of normalization of hemoglobin concentration in patients with chronic kidney disease.
24. Macdougall IC. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 2008;3:200-7
25. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008;19:411-9
26. McClellan WM, Frankenfield DL, Wish JB, et al.; End-Stage Renal Disease Core Indicators Work Group. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: results from the 1998 end-stage renal disease core indicators project. Am J Kidney Dis 2001;37:E36
27. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998;339:578-83
28. NKF-KDOQI Clinical Practice Guidelines for Anemia of Chronic Renal Failure IV. Administration of epoitein. Am J Kidney Dis 2001;37(Suppl 1):S2007
29. Locatelli F, Aljama P, Bárány P et al.; European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1-47
30. National Kidney Foundation. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:474-530
31. Working Party for European Best Practices Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Target Guideline II.1: what are the appropriate haemoglobin targets for anaemia treatment? Nephrol Dial Transplant 2004;19(Suppl 2):ii6
32. Gejyo F, Saito A, Akizawa T, et al.; Japanese Society for Dialysis Therapy. 2004 Japanese society for dialysis therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial 2004;8:443-59
33. Kalantar-Zadeh K, Aronoff GR. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol 2009;20:479-87 • Scholarly review on the clinical relevance of hemoglobin variability.
34. Gilbertson DT, Ebben JP, Foley RN, et al. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008;3:133-8
35. Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008;52:727-36
36. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999;33:821-8
37. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90 •• Large prospective randomized trial comparing partial and complete substitution of renal anemia in dialysis patients.
38. Churchill DN, Muirhead N, Goldstein M, et al. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol 1994;4:1809-13
39. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351:1403-8
40. McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008;48:1754-62
41. Eschbach JW, Cook JD, Scribner BH, Finch CA. Iron balance in hemodialysis patients. Ann Intern Med 1977;87:710-3
42. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for anemia in Chronic Kidney Disease. Am J Kidney Dis 2006;47(Suppl 3):S1
43. Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008;19:1599
44. Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int 2004;66:144-56
45. Kwan BC, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 2007;18:1246-61
46. Snyder CC, Collins AJ. KDOQI hypertension, dyslipidemia and diabetes care guidelines and current care patterns in the United States CKD population: National health and nutrition examination survey 1999-2004. Am J Nephrol 2009;30:44-54
47. Koren MJ, Davidson MH, Wilson DJ, et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis 2009;53:741-50
48. United States Renal Data System. Excerpts from USRDS 2008 Annual Data Report. U.S. Department of Health and Human Services. The National Institutes of Health, National Institut of Diabetes and Digestive and Kidney Diseases. Am J Kidney Dis 2009;53(Suppl 1):S47-64
49. Wanner C. Statin effects in CKD: "Is there a point of no return"? Am J Kidney Dis 2009;53:723-24 • Helpful comment focused on atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
50. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291:451-9
51. Seres DS, Strain GW, Hashim SA, et al. Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol 1993;3:1409-15
52. Blankestijn PJ, Vos PF, Rabelink TJ, et al. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 1995;5:1703-8
53. Wanner C, Bahner U, Mattern R, et al. Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. Nephrol Dial Transplant 2004;19:2570-751
54. Navaneethan SD, Nigwekar SU, Perkovic V. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 2009;2:CD004289
55. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48
56. Fellstroem BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407 •• International, multicenter, randomized, double-blind, prospective trial assessing the influence of rosuvastatin on cardiovascular events in patients undergoing HD.
57. Baigent C, Landry M. Study of heart and renal protection (SHARP). Kidney Int Suppl 2003;63:S207-10 • Study outline of a trial to assess the effects of cholesterol-lowering therapy with a combination of simvastatin and the cholesterol-absorption inhibitor ezetimide among around 9000 patients with CKD.
58. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004;17:365-70 •• Review on the use of insulin and oral medications to treat type 2 diabetes mellitus, focusing on dosing in patients with advanced kidney disease and ESRD.
59. Biesenbach G, Raml A, Schmekal B, et al. Decreased insulin requirement in relation to GFR in nephropathic type 1 and insulin-treated type 2 diabetic patients. Diabet Med 2003;20:642-45
60. K/DOQI workgroup. K/DOQI clinical practise guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005;4(Suppl 3):S1-153
61. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000;26(Suppl):73-85 • Scholarly review on various classes of drugs used in the pharmacological treatment of diabetic patients with CKD.
62. Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial 2000;13:4-8
63. Rave K, Heise T, Pfutzner A, et al. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care 2001;24:886-90
64. Skillman TG, Feldman JM. The pharmacology of sulfonylureas. Am J Med 1981;70:361-72
65. Balant L, Zahnd G, Gorgia A, et al. Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia 1973;9:331-38
66. Inoue T, Shibahara N, Miyagawa K, et al. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 2003;60:90-5
67. Nagai T, Imamura M, Iizuka K, et al. Hypogycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract 2003;59:191-94
68. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003;26:886-91
69. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis 2007;50:865-79
70. Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11:861-66
71. Manley HJ, Allcock NM. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy 2003;23:861-65
72. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
73. Fraser WD. Hyperparathyroidism. Lancet 2009;374(9684):145-58 • Scholarly review on pathophysiology of primary and secondary hyperparathyroidism and vitamin D deficiency.
74. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18
75. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;(113):S1-130
76. K/DOQI Clinical Practice Guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1
77. Schiller LR, Santa Ana CA, Sheikh MS, et al. Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 1989;320:1110-3
78. Wills MR, Savory J. Aluminium poisoning: dialysis encephalopathy, osteomalacia, and anaemia. Lancet 1983;2(8340):29-34
79. Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999;33:694-701
80. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52 • Randomized clinical trial comparing sevelamer with calcium-based phosphate binders in 200 HD patients.
81. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-24
82. Qunibi W, Moustafa M, Muenz LR, et al.; CARE-2 Investigators. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-65
83. Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005;68:2809-13
84. Persy VP, Behets GJ, Bervoets AR, et al. Lanthanum: a safe phosphate binder. Semin Dial 2006;19:195-9 • Scholarly review on lanthanum carbonate discussing its effects in bone, liver, and brain.
85. Quarles LD, Yohay DA, Carroll BA, et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994;45:1710-21
86. Moe SM, Kraus MA, Gassensmith CM, et al. Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. Nephrol Dial Transplant 1998;13:1234-41
87. Palmer SC, McGregor DO, Macaskill P, et al. Metaanalysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007;147:840-53 •• Meta-analysis assessing the value of vitamin D treatment for CKD patients with emphasis on mineral metabolism and cardiovascular and mortality outcome.
88. Palmer SC, McGregor DO, Craig JC, et al. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev 2009;(4):CD008175
89. Freundlich M, Quiroz Y, Zhang Z, et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008;74:1394-402
90. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56
91. Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-90
92. de Francisco AL, Piñera C, Palomar R, Arias M. Impact of treatment with calcimimetics on hyperparathyroidism and vascular mineralization. J Am Soc Nephrol 2006;17(12 Suppl 3):S281-5
93. Drüeke TB, Ritz E. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Clin J Am Soc Nephrol 2009;4:234-41 •• Outstanding review on the treatment of secondary hyperparathyroidism in CKD.
94. Messa P, Macário F, Yaqoob M, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3:36-45
95. Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008;3:1718-25
96. Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793-800
97. Chertow GM, Pupim LB, Block GA, et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007;2:898-905
98. Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 2009;4:1089-96 • Cross-sectional trial focusing on nonadherence and high pill burden in dialysis patients.
99. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
100. Karamanidou C, Clatworthy J, Weinman J, Horne RA. Systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 2008;9:2
101. Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chronic Kidney Dis 2008;15:123-32
102. Kimmel PL, Cukor D, Cohen SD, Peterson RA. Depression in end-stage renal disease patients: a critical review. Adv Chronic Kidney Dis 2007;14:328-34
103. Hirth RA, Greer SL, Albert JM, et al. Out-of-pocket spending and medication adherence among dialysis patients in twelve countries. Health Aff (Millwood) 2008;27:89-102
104. Bleyer AJ, Hylander B, Sudo H, et al. An international study of patient compliance with hemodialysis. JAMA 1999;281:1211-3
105. Singh AK, Szczech L, Tang KL, et al.; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98 •• Large prospective randomized trial comparing different hemoglobin levels in chronic kidney disease patients.
106. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32
107. Goldsmith D, Ritz E, Covic A. Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int 2004;66:1315-33
108. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52
109. Goldsmith DJ, Covic A, Sambrook PA, Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997;77:37-43